From needles to pills: oral GLP-1 therapy enters the obesity arena
Abstract Obesity remains a major global health challenge, driving type 2 diabetes, cardiovascular disease, and other complications. Despite effective lifestyle and surgical interventions, pharmacotherapy uptake has historically been limited. Injectable GLP-1 receptor agonists, including semaglutide...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BioMed Central
2025-10-01
|
| Schriftenreihe: | Cardiovascular Diabetology. Endocrinology Reports |
| Schlagworte: | |
| Online-Zugang: | https://doi.org/10.1186/s40842-025-00245-5 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|